Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation
Lawrence Cheng Kiat Ng, Jing Yuan Tan, Shin Yeu Ong, Chandramouli Nagarajan, Michelle Li Mei Poon, Aloysius Yew Leng Ho, Francesca Wei Inng Lim, Yunxin Chen · 2026
Read Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in asia: redefining the role of allogeneic haematopoietic stem cell transplantation by Lawrence Cheng Kiat Ng, Jing Yuan Tan, Shin Yeu Ong, Chandramouli Nagarajan, Michelle Li Mei Poon, Aloysius Yew Leng Ho, Francesca Wei Inng Lim, Yunxin Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13529884.txt.
Description
Lawrence Cheng Kiat Ng leads a 2026 report on brexucabtagene autoleucel, a CAR T-cell treatment for mantle cell lymphoma that has come back or stopped responding. The Singapore team describes five older patients treated during 2025 and sets their course beside earlier patients who received donor stem cell transplants.
Every treated patient responded, and most reached a complete response. Fever-like cytokine release occurred in most patients without severe cases, while one person had mild nerve-related side effects. Results compared well with the transplant group despite harder starting disease. The report presents early Asian real-world support for this cell therapy.
Catalog record
| CREATOR | Lawrence Cheng Kiat Ng, Jing Yuan Tan, Shin Yeu Ong, Chandramouli Nagarajan, Michelle Li Mei Poon, Aloysius Yew Leng Ho, Francesca Wei Inng Lim, Yunxin Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26755 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |